GTBP 8-K SEC Filing Analysis

Latest settled — T+5d

GTBP ▲ +0.45% at T+5d

SHORT call ✗ call lost -0.45% · α vs SPY +1.22% · entry $0.4400 → $0.4420

Next anchor: T+20d in 10d

Currently $0.4470 · -1.59% from $0.4400 entry (call sign-flipped)

Entry anchored
May 21, 03:59 PM ET
via Databento tick

T+1d

-10.91%

call +10.91% · α +11.49%

$0.3920

settled 18d ago

T+5d

+0.45%

call -0.45% · α +1.22%

$0.4420

settled 12d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regain the $1.00 minimum bid price requirement. The stock has been below $1 since at least November 2025, and the company previously restated financials in March 2026 due to a liability classification error. Delisting risk remains elevated if the bid price does not recover.

Actionable Insight

GTBP faces a high probability of delisting by November 16, 2026, unless the stock price recovers above $1 for 10 consecutive business days. The company has no disclosed reverse-split or capital-raise plan. Traders should expect continued downward pressure and potential OTC transfer. Monitor for any reverse-split announcement or capital infusion as the only realistic path to compliance.

Key Facts

Nasdaq granted an additional 180-day compliance period until November 16, 2026, to meet the $1.00 minimum bid price rule.
The initial 180-day compliance period (from November 20, 2025) expired on May 19, 2026, without compliance being achieved.
The company previously restated its Q2 and Q3 2025 financials on March 1, 2026, due to a $28.7M liability classification error on Greenshoe Rights.
Market cap is approximately $16M, and the stock has been trading below $1 for over six months.
The company stated it will monitor the bid price and assess options, but gave no specific plan to regain compliance.

Financial Impact

No specific financial impact quantified in the filing. The delisting risk alone threatens Nasdaq listing, which typically reduces institutional ownership and liquidity.

stock priceliquidityinstitutional ownership

Risk Factors

Failure to regain $1 bid price by November 16, 2026, will result in Nasdaq delisting and transfer to OTC markets.
The March 2026 restatement signals accounting control weaknesses, which may complicate any capital raise or reverse-split approval.
No specific compliance plan has been disclosed, increasing uncertainty around the timeline.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-024913
Document: 0001493152-26-024913-index-headers.html	0001493152-26-024913
Document: 0001493152-26-024913-index.html	0001493152-26-024913
Document: 0001493152-26-024913.txt	0001493152-26-024913

4 reports for GTBP

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for GTBP — sortable, filterable
	Type				Now
May 22, 2026 22d ago	8-K BEARISH ★ 7/10	$0.4400 $0.4420	▼ −0.45%	▲ +1.22%	$0.4470 (−1.59%)
Apr 30, 2026 6w ago	S-1 BEARISH ★ 7/10	$0.3430 $0.3750	▼ −9.33%	▼ −6.98%	$0.4470 (−30.32%)
Apr 7, 2026 9w ago	8-K NEUTRAL ★ 4/10	$0.4130 $0.3890	▼ −5.81%	▼ −11.14%	$0.4470 (+8.23%)
Mar 2, 2026 14w ago	Press Release MIXED ★ 5/10	$0.4670 $0.4170	▼ −10.71%	▼ −9.50%	$0.4470 (−4.28%)

US Market Status

Market Closed — Opens Mon (48h 45m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access